CuraSen Therapeutics secures USD54.5m in Series A financing
CuraSen Therapeutics, a privately held biotechnology company focussed on developing therapies to treat neurodegenerative diseases, has closed a USD54.5 million Series A financing Led by New Leaf Venture Partners. The investor syndicate also includes Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation –